Meiji Seika Pharma is expanding its mRNA vaccine production in Japan, which is a significant development in the country's fight against infectious diseases.
This expansion is a result of the company's partnership with Moderna, a leading mRNA vaccine developer.
Meiji Seika Pharma has been working closely with Moderna to develop and manufacture mRNA vaccines, including the COVID-19 vaccine.
The company's new production facility will enable it to produce larger quantities of mRNA vaccines, making them more accessible to people in Japan and potentially other countries.
A different take: Moderna
Invests in Arcalis to Boost mRNA Vaccine Production in Japan
Meiji Seika Pharma invests in ARCALIS to boost mRNA vaccine production in Japan. This strategic move aims to establish a comprehensive system for domestic mRNA vaccine production.
Meiji Seika Pharma has partnered with ARCALIS, a joint venture between Axcelead and Arcturus Therapeutics. ARCALIS is engaged in the development of mRNA pharmaceuticals and vaccines, as well as contract development and manufacturing organisation (CDMO) services.
The investment will strengthen the collaborative relationship between Meiji Seika Pharma and ARCALIS. The combination of ARCALIS' advanced technology and Meiji Seika Pharma's expertise in manufacturing will improve the supply of mRNA vaccines in Japan.
Meiji Seika Pharma plans to supply the domestically produced next-generation sa-mRNA vaccine 'KOSTAIVE' for Intramuscular Injection in December 2024. This vaccine will be formulated by a Meiji Seika Pharma Group company using the active pharmaceutical ingredient produced by ARCALIS.
The investment is a response to the lessons learned from the delays experienced in the development of COVID-19 vaccines during the pandemic. Meiji Seika Pharma and ARCALIS are committed to advancing the development, production, and supply of mRNA vaccines in line with the Japanese government's "Strategy for Strengthening Vaccine Development and Production Systems".
Corporate Changes
Meiji Seika Pharma has undergone significant changes in recent years. The company was formed as a result of a corporate reorganization within the Meiji Group.
In 2010, Meiji Holdings announced a reorganization plan, which involved splitting off Meiji Seika and Meiji Dairies to form two separate companies. Meiji Dairies took over the food and healthcare business of Meiji Seika, and Meiji Seika was renamed Meiji Seika Pharma Co., Ltd.
Meiji Seika Pharma is now a pharmaceutical company focused on developing and manufacturing healthcare products. According to Meiji Holdings, this reorganization aimed to create more focused and efficient business units within the group.
Meiji Seika Pharma has a rich history, dating back to the merger of Meiji and Seika in 2008. However, the reorganization in 2011 marked a significant turning point for the company.
The reorganization has enabled Meiji Seika Pharma to concentrate on its core pharmaceutical business and develop new products and services. This focus has helped the company to grow and become a leading player in the industry.
Here are some key facts about Meiji Seika Pharma's corporate changes:
- Meiji Holdings reorganized Meiji Seika and Meiji Dairies in 2011 to form Meiji Co., Ltd. (a food company) and Meiji Seika Pharma Co., Ltd. (a pharmaceutical company).
- Meiji Dairies took over the food and healthcare business of Meiji Seika as part of the reorganization.
- According to the International Cocoa Organization, Meiji is the 9th largest confectionery producer in the world.
Frequently Asked Questions
Is Meiji a Chinese company?
No, Meiji is not a Chinese company, it is a Japanese food company. Meiji is actually a well-established Japanese brand with a rich history.
Featured Images: pexels.com
